para que sirve el semaglutide Tod lo debes conocer sobre la #semaglutida #divulgacion #salud #consejofarmaceutico #apuntes #estudiante #farmacia Ozempic (Semaglutida)

News provided by Eli Lilly and Company Jun 06, 2026, 14:30 ET In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes common obesity-related conditions

Note that tirzepatide is marketed as Mounjaro when prescribed for type 2 diabetes management

Does exercise increase GLP-1 naturally

Discard the medication immediately if you observe any of the following: Particulate matter Color changes such as darkening or browning Crystallization Changes in viscosity These physical changes indicate chemical degradation or contamination

En el mercado existen frmacos como Wegoby, Ozempic, que han demostrado el potencial han demostrado el potencial de mejorar el control de la glucosa y favorecer la prdida de peso, siendo clave en el tratamiento de la obesidad y la diabetes tipo 2

For researchers comparing tirzepatide to other GLP-1 options, our semaglutide vs tirzepatide comparison provides a detailed head-to-head analysis including dosing differences and equivalent therapeutic levels